Next, the LSD1 inhibitor, GSK-LSD1, was selected for further evaluation of effects on proliferation due to its wide therapeutic window that has been previously demonstrated in multiple CNS tumors and confirmed in our MDA-GSC lines (26, 27). The gene discussed is KDM1A; the disease is central nervous system neoplasm.